Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial
新辅助 ARX788 联合吡咯替尼对比曲妥珠单抗、帕妥珠单抗、多西他赛和卡铂治疗 HER2 阳性乳腺癌:一项随机 2b 期试验
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-61213-2
Niu, Nan; Xue, Jinqi; Chen, Guanglei; Qiu, Fang; Xu, Qianshi; Zheng, Xinyu; Liu, Chao; Zhao, Yafei; Gu, Xi; Zhao, Yi; Xu, Hong; Zhang, Hao; He, Guijin; Li, Ke; Li, Pengfei; Chen, Xiaoying; Li, Yong; Wang, Shuo; Zhu, Demiao; Liu, Tong; Xing, Fei; Xu, Yongqing; Han, Ye; Tang, Meiyue; Liu, Mingxin; Jiao, Gege; Jiang, Xiaofan; Yuen, Tony; Pang, Zheng; Liu, Caigang